Comparison of immunosuppressive therapeutic regimens in patients with nephrotic syndrome due to idiopathic membranous nephropathy

Figures & data

TABLE 1.  Comparison of the baseline characteristics between the three study groups

Baseline	CYAMP	CPSMP	Lisinopril	p-Value
GFR (mL/min × 1.73 m^2)	81.6 ± 8	51.5 ± 7	65.7 ± 5.6	0.021
Proteinuria (g/24 h)	6.6 ± 1.0	7.0 ± 0.7	5.2 ± 0.8	0.291
Cholesterol (mg/dL)	403 ± 41	377 ± 21	355 ± 28	0.561
Albumin (g/dL)	2.7 ± 0.7	2.8 ± 0.2	2.2 ± 0.14	0.090

Note: GFR, glomerular filtration rate.

FIGURE 1. Percentage changes in the studied parameters from the baseline values.

TABLE 2.  Comparison of the end of study characteristics between the three study groups

End of study	CYAMP	CPSMP	Lisinopril	p-Value
GFR (mL/min × 1.73 m^2)	71.3 ± 8	62.0 ± 6	62.1 ± 6.3	0.557
Proteinuria (g/24 h)	2.4 ± 0.5	1.0 ± 0.4	2.0 ± 0.2	0.061
Cholesterol (mg/dL)	287 ± 61	285 ± 26	285 ± 23	0.998
Albumin (g/dL)	4.2 ± 0.5	4.2 ± 0.2	3.1 ± 0.2	<0.001

Note: GFR, glomerular filtration rate.

TABLE 3.  Comparison of the baseline and the end of study characteristics in the three study groups

	CYAMP			CPSMP			Lisinopril
	Baseline	End of study	p-Value	Baseline	End of study	p-Value	Baseline	End of study	p-Value
GFR (mL/min × 1.73 m^2)	81.6 ± 8	71.3 ± 8	0.034	51.5 ± 7	62.0 ± 6	0.033	65.7 ± 5.6	62.1 ± 6.3	0.56
Proteinuria (g/24 h)	6.6 ± 1.0	2.4 ± 0.5	0.003	7.0 ± 0.7	1.0 ± 0.4	<0.0001	5.2 ± 0.8	2.0 ± 0.2	0.002
Cholesterol (mg/dL)	403 ± 41	287 ± 61	0.005	377 ± 21	285 ± 26	0.017	355 ± 28	285 ± 23	0.002
Albumin (g/dL)	2.7 ± 0.7	4.2 ± 0.5	<0.0001	2.8 ± 0.2	4.2 ± 0.2	0.001	2.2 ± 0.14	3.1 ± 0.2	<0.0001

Note: GFR, glomerular filtration rate.

FIGURE 2. Mean eGFR levels of the three patient groups in different time-points of the study.

FIGURE 3. Mean 24-hour proteinuria levels of the three patient groups in different time-points of the study.